TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15007565

Group type: EXPERIMENTAL
Intervention: MRI and FDG PET imaging
Number of subjects: 101
Study: 11952478

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using verteporfin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transpupillary thermotherapy (TTT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-vascular endothelial growth factor (VEGF) agents
Number of subjects: 0
Study: 9465361

Group type: EXPERIMENTAL
Intervention: Health promotion intervention (Working Well Trial)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control worksites
Number of subjects: 40
Study: 7614522

Group type: EXPERIMENTAL
Intervention: Loracarbef 200 mg BID
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Loracarbef 400 mg BID
Number of subjects: 209
Study: 2645756

Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg once daily
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg once daily
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Benazepril 40 mg once daily
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Benazepril 80 mg once daily
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Thiazide diuretics
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 3
Study: 495045

Group type: EXPERIMENTAL
Intervention: hypertonic glycerol infusion plus dexamethasone
Number of subjects: 93

Group type: COMPARATOR
Intervention: dexamethasone alone
Number of subjects: 93
Study: 31784097

Group type: EXPERIMENTAL
Intervention: Percutaneous Zadek Osteotomy (ZO)
Number of subjects: 26
Study: 30939398

Group type: EXPERIMENTAL
Intervention: Adaptive n-back training (n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Less potent 1-back training (n = 10)
Number of subjects: 21
Study: 27696616

Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.1 mmol/kg)
Number of subjects: 60
Study: 26103528

Group type: EXPERIMENTAL
Intervention: 2 g intravenous cefazolin
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 3 g intravenous cefazolin
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both 2 g and 3 g intravenous cefazolin
Number of subjects: 26
Study: 23644855

Group type: EXPERIMENTAL
Intervention: glutamine+zinc+vitamin A
Number of subjects: 167

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 167
Study: 21875678

Group type: EXPERIMENTAL
Intervention: Sinovial(®) (16 mg/2 ml, 0.8% highly purified intra-articular hyaluronic acid)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Synvisc(®) (16 mg/2 ml, 0.8% hylan G-F20)
Number of subjects: 381
Study: 19053964

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control exercise
Number of subjects: 8
Study: 17388716

Group type: EXPERIMENTAL
Intervention: Cyproterone (100 mg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Haloperidol (2 mg/day)
Number of subjects: 27
Study: 17201083

Group type: EXPERIMENTAL
Intervention: Heparin-concentration-based system (HMS)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (standard ACT-based anticoagulation system)
Number of subjects: 39
Study: 12490774

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DIEPSS
Number of subjects: 0
Study: 10368245

Group type: EXPERIMENTAL
Intervention: 15 mL of 2% lidocaine gel administered intrarectally 15 min before biopsies (group 1)
Number of subjects: 109

Group type: COMPARATOR
Intervention: 15 mL of trans-sonic hydrophilic gel administered transrectally (placebo, group 2)
Number of subjects: 109
Study: 8683250

Group type: EXPERIMENTAL
Intervention: Oral cladribine 10 mg/m2/d for 5 consecutive days in monthly courses
Number of subjects: 63
Study: 1913759

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (0.3 mg sublingual)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Indomethacin (100 mg orally)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ibuprofen (800 mg orally)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6814225

Group type: EXPERIMENTAL
Intervention: Verapamil, 480 mg daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 30798781

Group type: EXPERIMENTAL
Intervention: Physical health and mental health measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fear of crime
Number of subjects: 0
Study: 30643924

Group type: EXPERIMENTAL
Intervention: 200 μg glucagon after 45 min of cycling
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 200 μg glucagon before cycling
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (resting)
Number of subjects: 14
Study: 27780647

Group type: EXPERIMENTAL
Intervention: Trained GPs
Number of subjects: 175

Group type: COMPARATOR
Intervention: Untrained GPs
Number of subjects: 175
Study: 26377322

Group type: EXPERIMENTAL
Intervention: Massage therapy (A)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Exercise therapy (B)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Exercise therapy plus massage therapy (C)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Advice to stay active (D)
Number of subjects: 600
Study: 23434505

Group type: EXPERIMENTAL
Intervention: Clinical high risk (CHR) for psychosis
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Clinical high risk (CHR) for psychosis with severe and psychotic symptoms (n = 10/53)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Healthy comparison (HC) subjects
Number of subjects: 53
Study: 21287368

Group type: EXPERIMENTAL
Intervention: Unsynchronized Nasal Intermittent Positive Pressure Ventilation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Head box oxygen, fraction of oxygen in inspired air was 50%
Number of subjects: 2
Study: 19646805

Group type: EXPERIMENTAL
Intervention: Self-learning video before 1-h chest compression-only CPR training
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: 1-h chest compression-only CPR training
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control group (no self-learning video)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control group after 1-h CPR training
Number of subjects: 214
Study: 17466939

Group type: EXPERIMENTAL
Intervention: Higher avoidant coping
Number of subjects: 146

Group type: COMPARATOR
Intervention: Lower avoidant coping
Number of subjects: 146
Study: 15208206

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy based on estrogen receptor content
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 16200721

Group type: EXPERIMENTAL
Intervention: Soybean lecithin 10 g tid
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Citicoline
Number of subjects: 542

Group type: COMPARATOR
Intervention: Conventional treatment (Basic treatment group)
Number of subjects: 542
Study: 9635386

Group type: EXPERIMENTAL
Intervention: premixed insulin administered by pen
Number of subjects: 93

Group type: COMPARATOR
Intervention: self‐mixed/syringe, premixed/syringe, self‐mixed/pen, premixed/pen
Number of subjects: 93
Study: 7944878

Group type: EXPERIMENTAL
Intervention: m-Chlorophenylpiperazine (MCPP) 0.1 mg/kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: yohimbine hydrochloride 0.4 mg/kg
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo (saline solution)
Number of subjects: 22
Study: 2828139

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 7
Study: 30908879

Group type: EXPERIMENTAL
Intervention: Dual perfusion (DP) via both the hepatic artery and portal vein
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard perfusion (SP) via only the portal vein
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Dual perfusion (DP)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard perfusion (SP)
Number of subjects: 124
Study: 28837906

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Balanced General Anesthesia
Number of subjects: 19
Study: 25468636

Group type: EXPERIMENTAL
Intervention: Double low protocol (iodixanol at 270 mg iodine/ml, 100 kVp tube voltage, AIDR)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Conventional protocol (iopamidol at 370 mg iodine/ml, 120 kVp tube voltage, FBP)
Number of subjects: 179
Study: 24176436

Group type: EXPERIMENTAL
Intervention: Community health education and access to subsidized salt substitute in 60 intervention villages.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual practices in control villages (30 villages).
Number of subjects: 120
Study: 20821237

Group type: EXPERIMENTAL
Intervention: RAPID® 5 Access software (Quickview mode)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: RAPID® 5 Access software (auto mode and single image at 12 fps)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: RAPID® 5 Access software (Quickview and Quadview modes)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: RAPID® 5 Access software (overall)
Number of subjects: 44
Study: 19264928

Group type: EXPERIMENTAL
Intervention: Assistive software homophone tool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Homophones highlighted only
Number of subjects: 0

Group type: COMPARATOR
Intervention: No help
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 17257782

Group type: EXPERIMENTAL
Intervention: Motivated Stepped Care (MSC) + Contingent Voucher Incentives (CVI)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Contingent Voucher Incentives (CVI)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Motivated Stepped Care (MSC)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 236
Study: 14727206

Group type: EXPERIMENTAL
Intervention: Rifampin-pyrazinamide (RZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 12145595

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 100
Study: 10467322

Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells (PBSC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bone marrow (BM)
Number of subjects: 30
Study: 8751023

Group type: EXPERIMENTAL
Intervention: Grapefruit juice taken simultaneously with felodipine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Grapefruit juice taken 1 hour before felodipine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Grapefruit juice taken 4 hours before felodipine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Grapefruit juice taken 10 hours before felodipine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Grapefruit juice taken 24 hours before felodipine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Concomitant water and felodipine intake
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All treatments including grapefruit juice
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Treatments including grapefruit juice
Number of subjects: 9
Study: 2236369

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural therapy (average number of sessions: 7.2)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Assessment only (control group)
Number of subjects: 31
Study: 686894

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462

Group type: COMPARATOR
Intervention: Hexachlorophene-ethanol
Number of subjects: 462
Study: 30335626

Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg twice daily, n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 80
Study: 28132796

Group type: EXPERIMENTAL
Intervention: Guidewire insertion to 15cm
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Guidewire insertion to 17.5cm
Number of subjects: 69

Group type: COMPARATOR
Intervention: Guidewire insertion to 20cm
Number of subjects: 69
Study: 25457902

Group type: EXPERIMENTAL
Intervention: 3 mg macitentan
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: 10 mg macitentan
Number of subjects: 742

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 742
Study: 23660263

Group type: EXPERIMENTAL
Intervention: One-vessel group (n = 106)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Two-vessel group (n = 120)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Three-vessel group (n = 442)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Male group
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Multi-Logistic regression analysis
Number of subjects: 784

Group type: COMPARATOR
Intervention: Control group (n = 116)
Number of subjects: 784
Study: 21854292

Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment (group counseling weeks 1-8 + transdermal nicotine patch 21 mg/day weeks 1-6; 14 mg/day weeks 7-8)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Substance abuse treatment as usual
Number of subjects: 153
Study: 19703850

Group type: EXPERIMENTAL
Intervention: Direct CT arthrography
Number of subjects: 126
Study: 17596218

Group type: EXPERIMENTAL
Intervention: ketamine-propofol admixture (0.5 mg/ml ketamine in 10 mg/ml propofol)
Number of subjects: 116

Group type: COMPARATOR
Intervention: lidocaine-propofol admixture (1 mg/ml lidocaine in 10 mg/ml propofol)
Number of subjects: 116
Study: 15294063

Group type: EXPERIMENTAL
Intervention: Pulmicort Turbuhaler (budesonide inhalation powder) two puffs (400 microg) bid
Number of subjects: 0

Group type: COMPARATOR
Intervention: pressurized metered-dose inhalers (pMDIs)
Number of subjects: 0
Study: 11775646

Group type: EXPERIMENTAL
Intervention: Essaven gel (EG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9169397

Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment (insulin-glucose infusion for at least 24 hours followed by multidose insulin treatment)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment (in predefined group without previous insulin treatment and low cardiovascular risk)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Standard treatment (control group in predefined group without previous insulin treatment and low cardiovascular risk)
Number of subjects: 620
Study: 1316404

Group type: EXPERIMENTAL
Intervention: Benazepril (10 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3921727

Group type: EXPERIMENTAL
Intervention: Abstinence from alcohol for six weeks, followed by resuming usual alcohol intake for five weeks.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual level of alcohol intake throughout the trial.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resuming alcohol intake after six weeks of abstinence.
Number of subjects: 24
Study: 31931236

Group type: EXPERIMENTAL
Intervention: ΔSo2 (v - jv) on day 3 in nonsurvivor group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ΔSo2 (v - jv) on day 3 in survivor group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ΔSo2 (v - jv) on day 1 in nonsurvivor group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ΔSo2 (v - jv) on day 1 and day 3 in unfavorable neurologic outcome group
Number of subjects: 90
Study: 30819700

Group type: EXPERIMENTAL
Intervention: Ultrabrief intervention (UBI) with three structured appointments over 5 weeks.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Practice as usual (PAU) without UBI training.
Number of subjects: 160
Study: 28361971

Group type: EXPERIMENTAL
Intervention: PG2 (500 mg, IV) administered 3 doses per week for 2 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: PG2 placebo
Number of subjects: 61
Study: 25724233

Group type: EXPERIMENTAL
Intervention: STN DBS
Number of subjects: 0

Group type: COMPARATOR
Intervention: GPi DBS
Number of subjects: 0
Study: 23433461

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy for 48 months (clopidogrel plus aspirin)
Number of subjects: 1966

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy for 12 months (clopidogrel plus aspirin)
Number of subjects: 1966
Study: 20592662

Group type: EXPERIMENTAL
Intervention: Phentermine (abrupt cessation)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Amphetamine dependence (control group)
Number of subjects: 35
Study: 20009826

Group type: EXPERIMENTAL
Intervention: Innervated free TRAM flap
Number of subjects: 27

Group type: COMPARATOR
Intervention: Noninnervated free TRAM flap
Number of subjects: 27
Study: 17111319

Group type: EXPERIMENTAL
Intervention: Moderately intense activities (> 4 METs) for at least 210 min a week (4 M (210))
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: More intense activities (> 6 METs) for at least 60 min a week (6 M (60))
Number of subjects: 67
Study: 15098218

Group type: EXPERIMENTAL
Intervention: Nursing intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 12577352

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Guben Yiliu III (GBYL)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with moxibustion and Guben Yiliu III (GBYL)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Chemotherapy alone (Control group)
Number of subjects: 81
Study: 9436636

Group type: EXPERIMENTAL
Intervention: CEOP‐Bleo regimen (cyclophosphamide, vincristine, epirubicin, prednisone and bleomycin)
Number of subjects: 169

Group type: COMPARATOR
Intervention: CIOP‐Bleo regimen (idaurubicin instead of epirubicin)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: CEOP‐Bleo regimen
Number of subjects: 169

Group type: COMPARATOR
Intervention: CIOP‐Bleo regimen
Number of subjects: 169
Study: 8357509

Group type: EXPERIMENTAL
Intervention: Reach Wonder Grip toothbrush
Number of subjects: 68

Group type: COMPARATOR
Intervention: Colgate Plus Junior toothbrush
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Preference questionnaire
Number of subjects: 68
Study: 2427836

Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg (pretreatment)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Atenolol and Propranolol
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 34
Study: 2557481

Group type: EXPERIMENTAL
Intervention: Conventional amount of bicarbonate (33 +/- 2 mmol/liter) in the dialysate (Group A)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Higher amount of sodium bicarbonate (7 to 15 mmol/liter) added to the dialysate to obtain 24 mEq predialysis bicarbonate plasma levels (Group B)
Number of subjects: 21
Study: 31413183

Group type: EXPERIMENTAL
Intervention: READY (n=53)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control (n=54)
Number of subjects: 107
Study: 27396432

Group type: EXPERIMENTAL
Intervention: Blanketing
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-blanketing
Number of subjects: 28
Study: 25187399

Group type: EXPERIMENTAL
Intervention: Bapineuzumab (6 doses intravenously once every 13 weeks)
Number of subjects: 1458
Study: 23448278

Group type: EXPERIMENTAL
Intervention: GSK2239633 100 μg intravenous infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: GSK2239633 150-1500 mg oral doses
Number of subjects: 30
Study: 21503852

Group type: EXPERIMENTAL
Intervention: Dental loupes (2.5×, LED headlight)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No dental loupes
Number of subjects: 22
Study: 18353720

Group type: EXPERIMENTAL
Intervention: Carperitide infusion (group II)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nitroglycerin (group I)
Number of subjects: 75
Study: 16507741

Group type: EXPERIMENTAL
Intervention: Active dissemination of the North American Guidelines for Children's Agricultural Tasks (NAGCAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 14692210

Group type: EXPERIMENTAL
Intervention: Colgate Total Advanced Fresh toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercially available fluoride breath-freshening toothpaste
Number of subjects: 0
Study: 10869261

Group type: EXPERIMENTAL
Intervention: Cariporide (40 mg intravenous bolus)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9374084

Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2 intravenously over 3 hours for eight cycles over 24 weeks
Number of subjects: 209

Group type: COMPARATOR
Intervention: Standard treatment with oral cyclophosphamide 100 mg/m2/d days 1 to 14, intravenous methotrexate 40 mg/m2 days 1 and 8, intravenous 5‐fluorouracil 600 mg/m2 days 1 and 8, and oral prednisone 40 mg/m2 daily days 1 to 14 (CMFP) for six cycles over 24 weeks
Number of subjects: 209
Study: 1546547

Group type: EXPERIMENTAL
Intervention: Clomipramine (25‐75 mg; flexible dosage)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 40
Study: 2580694

Group type: EXPERIMENTAL
Intervention: Go stimuli (response production)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: No-Go stimuli (response inhibition)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: No-Go stimuli
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Counting Go stimuli
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Button pressing for Go stimuli
Number of subjects: 12
Study: 29516192

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 258
Study: 27881106

Group type: EXPERIMENTAL
Intervention: Multifamily therapy (MFT-AN)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Single family therapy (FT-AN)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 169
Study: 25011421

Group type: EXPERIMENTAL
Intervention: SHED-IT intervention groups
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 159
Study: 22709755

Group type: EXPERIMENTAL
Intervention: Ranolazine (1,000 mg twice daily for 7 days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70